ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1471

TNFα Influences the Status of B and T Cells By Acting on BCR and TCR Pathways Via RasGRP1 and RasGRP3 Proteins

Marie-Laure Golinski1, Martine Hiron2, Céline Derambure2, Clément Guillou1, Manuel Fréret2, Olivier Boyer3, Olivier Vittecoq4 and Thierry Lequerré5, 1Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, 2Inserm 905 & Institute for Biomedical Research, University of Rouen, Rouen, France, Rouen, France, 3Immunology, INSERM U905, University of Rouen, Rouen, France, 4Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, 51 Rue De Germont, Chu De Rouen, Rouen, France

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: B cells, T cells and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose Rheumatoid arthritis (RA) is the most common inflammatory arthritis. B and T cells play a key role in the RA pathophysiology. RasGRP is a member of the CDC25 family of Ras guanyl nucleotide exchange factors. RasGRP1 is expressed in T and B cells whereas RasGRP3 is only expressed in B cells. In previous studies, we have shown that RasGRP3 geneexpression level significantly decreased in peripheral blood mononuclear cells from RA patients responders to adalimumab and etanercept (anti-TNFa drugs), leading to the question of TNFα involvement in RasGRP1 and RasGRP3 pathways. To study TNFα effects on RasGRP1 and RasGRP3 expression levels in vitro.

Methods We measured, by qRT-PCR and western-blot, RasGRP1 and RasGRP3 expression levels in B and T cells isolated from buffy coat. In each condition, cells were cultured with or without TNFα for 24 or 48 hours. Cell proliferation was evaluated by [3H] thymidine incorporation. To investigate the TNFα implication on signaling pathways, MAPK and apoptosis protein arrays were used.

Results In B cells, TNFα induced an increase of RasGRP1 and RasGRP3 gene expression levels without effect on B cells proliferation and BCR pathway phosphorylations, but apoptotic pathways were inhibited. In T cells, TNFα increased RasGRP1 gene expression level but RasGRP1 protein expression level decreased, inhibiting T cell proliferation and TCR pathway phosphorylations.

Conclusion This study suggests a link, never described previously, between RasGRP1 or RasGRP3 and the TNFa’ effects on T and B cells. While the response to anti-TNFα treatments in RA patients modulates RasGRP3 gene expression, TNFα inhibits RasGRP1 protein expression leading to TCR pathway inhibition, in vitro, in pathophysiological condition. The better understanding of TNFα effects on RasGRP proteins could permit a better understanding of the mechanisms of action of TNFα blocking agents on T and B cells.


Disclosure:

M. L. Golinski,
None;

M. Hiron,
None;

C. Derambure,
None;

C. Guillou,
None;

M. Fréret,
None;

O. Boyer,
None;

O. Vittecoq,
None;

T. Lequerré,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tnf%ce%b1-influences-the-status-of-b-and-t-cells-by-acting-on-bcr-and-tcr-pathways-via-rasgrp1-and-rasgrp3-proteins/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology